Lancet
-
Multicenter Study
Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.
Long-term intraocular injections of vascular endothelial growth factor (VEGF)-neutralising proteins can preserve central vision in many patients with neovascular age-related macular degeneration. We tested the safety and tolerability of a single intravitreous injection of an AAV2 vector expressing the VEGF-neutralising protein sFLT01 in patients with advanced neovascular age-related macular degeneration. ⋯ Sanofi Genzyme, Framingham, MA, USA.
-
Multicenter Study
Mortality risks associated with emergency admissions during weekends and public holidays: an analysis of electronic health records.
Weekend hospital admission is associated with increased mortality, but the contributions of varying illness severity and admission time to this weekend effect remain unexplored. ⋯ NIHR Oxford Biomedical Research Centre.